This segment focuses on developing novel therapeutics that selectively modulate the immune system through cytokine pathways. Nektar's research and development efforts in this area involve creating targeted therapies that can enhance or suppress specific immune responses to treat autoimmune diseases, inflammatory conditions, and certain types of cancer. The company utilizes its advanced polymer conjugate technologies to improve the pharmacokinetic and pharmacodynamic properties of cytokine-based drugs, enhancing their efficacy and reducing potential side effects. Clinical trials are underway to evaluate the safety and efficacy of these investigational medicines in various immunological disorders, with the goal of improving patient outcomes and quality of life. Partnerships with other pharmaceutical companies are crucial for expanding the reach and impact of these innovative therapies.

Nektar's oncology segment is dedicated to developing innovative cancer treatments that leverage the body's immune system to fight tumors. This involves research into immuno-oncology approaches, including cytokine-based therapies and toll-like receptor agonists, designed to stimulate anti-tumor immune responses. The company's pipeline includes investigational medicines in various stages of clinical development, targeting different types of cancer, such as melanoma, renal cell carcinoma, and non-small cell lung cancer. Nektar employs advanced drug delivery technologies to enhance the efficacy and safety of its oncology therapeutics, aiming to improve patient survival rates and reduce the burden of cancer. Clinical collaborations with other pharmaceutical companies are essential for advancing the development and commercialization of these novel cancer treatments.